Bone Abstracts

Introduction: Despite similarities in upfront treatment, impairment of bone mineral density(BMD) varies in long-term adult survivors of childhood cancer (CCS). We studied for the first time whether genetic variation is involved in impairment of BMD in adult long-term CCS.Method: This cross-sectional single-center cohort study included 334 adult CCS (median follow-up time: 15.2 years (range 5.1–39.8); median age at follow-up: 26.1 years (range 18.1&#...

Multiple myeloma (MM) bone disease is characterized by lytic bone lesions that contribute to patient morbidity and mortality after patients are in complete remission. The mechanisms mediating this long-term osteoblast (OB) suppression are poorly understood. We hypothesized that MM cells induce epigenetic changes at the Runx2 promoter in preOB bone marrow stromal cells (BMSC). We demonstrated that Gfi1, a transcriptional repressor of Runx2 that is induced in B...

Background: Low total body BMD (TB-BMD) is an established risk factor for fractures in healthy children. However, bone strength depends not only on bone mass and density, but also on the structural geometry of bones. Hip structural analysis (HSA) is a technique applied on hip DXA scans to calculate several bone geometry parameters. The aim of our study was to evaluate other bone geometrical parameters that can constitute determinants of fracture risk. Specifically, we examined...

Aim: The aim of the research is to define the bone mineral density in patients, with Parkinson’s disease.Methods: We examined 12 women with Parkinson’s disease and 12 healthy women of appropriate age (average age: −63.6±6.25 vs 62.2±6.83 years, P=0.5). The duration of Parkinson’s disease was at list 5 years. All patients reseived levodopa.Results: BMD of women with Parkinson’s disease wa...

The first step to getting started as a post-doc is finding an appealing post-doc position. Be proactive and begin the search and application process early. One of the most critical aspects to think about is the research area. It should be something that excites you and something where you can imagine to work in for the next couple of years. Once you have decided on a research area, you can start thinking about choosing an adviser. The adviser has great power to help build a ca...

Diabetes mellitus results in increased skeletal fragility through reduced bone mineral density and altered collagen structure. How these changes affect bone mechanics at the tissue level remains largely unclear. Anti-osteoporosis medications improve bone mass, but whether they can fully restore tissue strength in diabetic bone, where collagen quality is compromised, has not been fully elucidated. The objective of this study was to determine the effect of type 2 diabetes mellit...

The exposition of shift workers to light at night supresses the melatonin (ME) production. ME supression may contribute to the development of osteoporosis, which can be prevented and treated by resistance exercise (RE). This study evaluated the effect of ME release supression by pineal gland (pinealectomy) and the RE on rats tibiae morphology, mineral quantification and mechanical parameters. The project was approved by the local ethics committee (protocol 2014-00939). Fourty ...

Background: Observations in rodents suggest that osteocalcin (OC) participates in glucose metabolism. Data from human studies are inconclusive and it remains unclear whether OC is simply a marker of bone turnover (BTM) or if it also mediates interactions between the skeleton and glucose homeostasis. This study determined the responses of BTMs, including OC, to oral glucose tolerance test (OGTT) in obese and normal-weight subjects.Materials and methods: P...

Introduction: Parathyroid hormone (PTH) measurement is of use in i) differential diagnosis of hypercalcaemia and ii) patients with renal impairment at risk of bone disease. PTH immunoassays are complicated by cross-reactivity with truncated (inactive) variant forms, which accumulate in patients with renal impairment. PTH assay variability is a critical governance issue in renal medicine, suggesting an MS-based reference method is required.Aim: To develop...

Denosumab (DMAb) has a unique profile of bone resorption inhibition: CTX decreases rapidly by 3 days and inhibition is released at the end of the 6-month dosing interval, when DMAb serum levels decrease (McClung NEJM 2006). The dynamic CTX inhibition profile is not curtailed by continued treatment. In the 3-year FREEDOM study, CTX values at 6 months were influenced by baseline CTX values and days since the 1st injection (Eastell JBMR 2011). With 3 additional ...